Ocular therapy company Tarsius Pharma revealed on Monday the receipt of a highly competitive HRIZON 2020 Grant, valued at EUR2.4m, to support the first-in-human clinical trial of its novel drug TRS01.
The EUR2.4m HRIZON 2020 Grant was awarded by the European Commission.
According to the company, it implements a patented, proprietary new molecule to 're-engineer' the immune system. TRS, which is its bio-inspired technology, approaches inflammatory diseases from within the immune system and helps in treating blinding ocular diseases.
In addition, the company's TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Untreated, these diseases can have devastating effects and may eventually lead to blindness.
Roivant to announce Q3 2026 financial results
HUTCHMED reports positive Phase III results for sovleplenib in wAIHA
Physiomics secures follow-on UK contract for Phase 2 study support
Amgen's UPLIZNA receives US FDA approval
Physiomics secures new contract with Numab Therapeutics for preclinical antibody development
InduPro secures strategic investment and collaboration with Sanofi to advance autoimmune therapy
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
AstraZeneca to invest USD2bn in major Maryland manufacturing expansion
European Commission approves Celltrion's Remsima IV liquid formulation
TIRmed Pharma partners with Bachem to advance production of atopic dermatitis therapy
Fondazione Telethon reports positive opinion for Waskyra marketing authorisation in Europe
Vascarta and CUNY report positive preclinical results in glioblastoma treatment